

A synthesis of phosphonate derivatives using multicomponent reaction of oxalyl chloride

Mahboubeh Ghasemian Dazmiri*a, Maryam Ghazvini^b and Samaneh Sadat Sharifi^c

^aDepartment of Chemistry, Faculty of Sciences, Babolsar University, Mazandaran, Iran

^bChemistry Department, Payam Noor University, Tehran, Iran

c Department of Chemistry, Faculty of Sciences, Sistan and Baluchestan University, Sistan and Baluchestan, Iran

Received: February 2021; Revised: March 2021; Accepted: March 2021

Abstract: In this research, phosphonate derivatives were produced from the reaction of aniline, oxalylchloride, malononitrile, activated acetylenic compounds and trialkyl(aryl) phosphites in water at room temperature in excellent yields.

Keywords: Acetylenic esters, oxalylchloride, Phosphonates, Aniline, Five-component reaction.

Introduction

Heterocyclic compounds hold a prominent position in medicinal chemistry owing to their wide spectrum of biological activities such antimalarial,[1] as antimicrobial, [2] antitumor.[3] anticancer. [4] antidepressant,[5] antiviral,[6] antidiabetic,[7] antiinflammatory [8] and anti-HIV. [9] Moreover, they also contribute in the feld of material science, [10] dyes and pigment science [11] as well as agrochemistry [12]. Therefore, there is considerable thrust for the development of efficient synthetic strategies for producing these compounds. MCRs open diverse avenues to create novel concatenations in one pot fashion leading to diverse biologically potent heterocyclic scaffolds [13, 14]. Having a cascade of reactions occurring in one pot is highly beneficial in the context of modern trends for organic synthesis, where sustainability is as relevant as efficiency and selectivity. Multicomponent reactions being atom economic, efficient and extremely convergent in nature offer a number of advantages over stepwise sequential approaches [15–17].

Organophosphorus compounds are synthetic targets of interest, not least because of their value for a variety of industrial, biological, and chemical synthetic uses [18-24]. The physical properties and chemical reactivity of phosphate esters interlinks many areas in chemistry and biology. Introduction of a phosphate monoester into a molecule such as a drug candidate enhances the water solubility, hence altering its bioavailability [25-27]. As a result, a large number of methods have appeared describing novel syntheses of organophosphorus compounds [27]. There are many studies on the reaction between trivalent phosphorus nucleophiles and α , β -unsaturated carbonyl compounds in the presence of a proton source such as alcohol or [28-29].The phenol reaction of aniline 1. oxalylchloride 2, malononitrile 3, activated acetylenic compounds 4 and trialkyl(aryl) phosphites 5 proceeds smoothly in water at room temperature to produce phosphonate derivatives 6 in 90-95% yields (Scheme 1).

^{*}Corresponding author. Tel.: +989112552650; E-mail: pghm49@yahoo.com.



Scheme 1: Synthesis of phosphonate derivatives 6

Results and discussion

The reaction of aniline 1, oxalylchloride 2, malononitrile 3, activated acetylenic compounds 4 and trialkyl(aryl) phosphites 5 proceeds smoothly in water at room temperature to produce phosphonate derivatives 6 in 90-95% yields (Scheme 1). The structures of compounds 6a-6e as 1:1:1 adducts were apparent from their mass spectra, which displayed, in each case, the molecular ion peak at appropriate m/zvalues. The ¹H- and ¹³C NMR spectroscopic data, as well as IR spectra, are in agreement with the proposed structures. The ¹H NMR spectrum of **6a** exhibited two doublets readily recognized as arising from the two diastereotopic methoxy ($\delta = 2.85$ ppm, ${}^{3}J_{HP} = 11$ Hz and $\delta = 3.67$ ppm, ${}^{3}J_{\rm HP} = 11$ Hz) groups. The two singlets at $\delta = 3.71$ and 3.82 ppm belong to the ester methoxy protons. The proton-decoupled ¹³C NMR spectrum of **6a** showed sixteen distinct resonances in agreement with the proposed structure. Observation of ${}^{3}J_{\rm HH}$ 13 Hz for the vicinal methine protons in **6a**

indicates the dominance of the *anti* arrangement. Since compound **6a** possesses two stereogenic centers, two diastereomers with *anti* HCCH arrangement are possible. The observation of ${}^{3}J_{CP} = 24$ Hz for $CO_{2}Me$ group in agreement with the (2R, 3S) or (2S, 3R) diastereoisomer. Thus, the reaction is diastereoselective.

Although we have not established the mechanism of the reaction between trialkyl(aryl) phosphites and propiolate in the presence of intermediate which is produced from the isatin 7 with malononitrile 3 in an experimental manner, a possible explanation is proposed in Scheme 2. The first step may involve addition of trialkyl(aryl) phosphits to the acetylenic ester and formation of the 1:1 adducts 9 and its subsequent protonation by isatin. Then, the positively charged ion 10 is attacked by the anion of the NH-acid 11 to produce 6 (Scheme 2).



Scheme 2: Proposed mechanism for generation of 6

Conclusion

In summary, the reaction of aniline 1, oxalylchloride 2, malononitrile 3, activated acetylenic compounds 4 and trialkyl(aryl) phosphites 5 proceeds smoothly in water at room temperature to produce phosphonate derivatives 6 in excellent yields. The present procedure has the advantage that the reaction is performed under neutral conditions, and the starting material can be used without any activation or modification.

Experimental

General.

All of compounds were obtained from Fluka and were used without further purification. M.p.: Electrothermal-9100 apparatus. IR spectra: Shimadzu IR-460 spectrometer. ¹H-, ¹³C-, and ³¹P NMR spectra: Bruker DRX-500 AVANCE instrument; in CDCl₃ at 500.1, 125.7, and 202.4 MHz, respectively; \Box in ppm, *J* in Hz. EI-MS (70 eV): Finnigan-MAT-8430 mass spectrometer, in *m*/*z*. Elemental analyses (C, H, N) were performed with a Heraeus CHN-O-Rapid analyzer.

General Procedure for the Preparation of Compounds **6**

To a stirred solution of aniline 1 (2 mmol), oxalylchloride 2 (2 mmol), under solvent-free conditions. After 30 min malononitrile 3 (2 mmol) was added drop-wise to previous mixture. The mixture was then allowed to warm to rt, and stirred for 30 min. Then activated acetylenic compounds 4 (2 mmol) and phosphite 5 (2 mmol) was added and final mixture was stirred for 2 h. after completion of the reaction, water (5 mL) was poured to mixture of reactions and the precipitate was separated by filtration and purified by column chromatography (SiO₂; *n*-hexane/AcOEt 4:1) to afford the pure adducts.

Dimethyl 2-(dimethoxyphsphoryl)-3-(2,3-dioxo-2,3-dihydro-(1H)-indol-1-yl)-succinates (**6a**, C₁₆H₁₈NO₉P):

Orange powder, mp 124-126°C; yield 0.71 g, 89%; IR (KBr): \overline{V} = 1725, 1610 cm⁻¹; ¹H NMR: 2.85 (d, ³*J*_{HP} = 11.0, OMe), 3.67 (d, ³*J*_{HP} = 11.0, OMe), 3.71 (s, OMe), 3.82 (s, OMe), 4.30 (1 H, dd, ³*J*_{HH} = 13.0, ²*J*_{HP} = 21.4, CH), 5.69 (dd, ³*J*_{HH} = 13.0, ³*J*_{HP} = 9.9, CH), 7.21 (t, ³*J*_{HH} = 7.2, 2 CH), 7.51 (t, ³*J*_{HH} = 7.5, CH), 7.54 (d, ³*J*_{HH} = 7.5, CH) ppm; ¹³C NMR: 44.5 (d, ¹*J*_{CP} = 131.9, CH), 51.9 (d, ²*J*_{CP} = 7.0, CH), 52.7 (d, ²*J*_{PC} = 7, OMe), 53.9 (d, ²*J*_{PC} = 7, OMe), 53.1 (OMe), 53.3 (OMe), 111.3 (2 CH), 117.9 (C), 124.0 (CH), 125.2 (C), 137.9 (CH), 160.9 (C=O), 166.5 (d, ²*J*_{CP} = 13.2, C=O), 170.5 (d, ³*J*_{CP} = 4.0, C=O), 181.7 (C=O) ppm; ³¹P NMR: 11.65 ppm; EI-MS: 399 (M⁺, 15), 368 (62), 290 (100), 253 (38), 146 (88), 109 (86), 31 (56).

Dimethyl 2-(*diethoxyphsphoryl*)-3-(2,3-*dioxo*-2,3*dihydro*-(1H)-*indo*l-1-*y*])-succinates (**6b**, C₁₈H₂₂NO₉P):

Yellow powder, mp 127-129°C; yield 0.80 g, (94%); IR (KBr): \overline{V} = 1730, 1602 cm⁻¹; ¹H NMR: 1.13 (t, ³*J*_{HH} = 7.1, Me), 1.15 (t, ³*J*_{HH} = 7.1, Me), 3.71(s, OMe), 3.85 (s, OMe), 3.93 (m, OCH₂), 3.97 (m, OCH₂), 4.28 (dd, ${}^{3}J_{HH} = 12.2$, ${}^{2}J_{HP} = 21.6$, CH), 5.74 (dd, ${}^{3}J_{HH} = 12.2$, ${}^{3}J_{HP} = 9.6$, CH), 7.06 (d, ${}^{3}J_{HH} = 7.5$, CH), 7.14 (t, ${}^{3}J_{HH} =$ 7.5, CH), 7.60 (t, ${}^{3}J_{HH} = 7.6$, CH), 7.64 (d, ${}^{3}J_{HH} = 7.5$, CH) ppm; 13 C NMR: 15.9 (d, ${}^{3}J_{CP} = 6.1$, Me), 16.1 (d, ${}^{3}J_{CP} = 6.0$, Me), 43.8 (d, ${}^{1}J_{CP} = 130.9$, CH), 52.7 (d, ${}^{2}J_{CP} =$ 7.0, CH), 53.6 (OMe), 53.1 (OMe), 63.5 (d, ${}^{2}J_{CP} =$ 7.1, OCH₂), 63.6 (d, ${}^{2}J_{CP} = 7.1$, OCH₂), 110.9 (2 CH), 118.1 (C), 123.9 (CH), 125.5 (C), 138.2 (CH), 160.1 (C=O), 167.5 (d, ${}^{2}J_{CP} = 14.2$, C=O), 170.1 (d, ${}^{3}J_{CP} =$ 10.1, C=O), 181.9 (C=O) ppm; 31 P NMR: 17.28. EI-MS: 427 (M⁺, 5), 395 (52), 340 (100).

Dimethyl 2-(2,3-*dioxo*-2,3-*dihydro*-(1*H*)-*indo*l-1-*y*])-3-(*diphenoxyphsphory*])-succinates (**6c**, C₂₆H₂₂NO₉P):

Yellow crystals, mp 132-134°C; yield 0.96 g, 92%; IR (KBr): $\overline{V} = 1729$, 1603 cm⁻¹; ¹H NMR: 3.72 (s, OMe), 3.85 (s, OMe), 4.62 (dd, ³J_{HH} = 12.0, ²J_{HP} = 21.1, CH), 5.51 (dd, ³J_{HH} = 12.1, ³J_{HP} = 9.2, CH), 6.87 (d, ³J_{HH} = 7.6, 2 CH), 6.93 (d, ³J_{HH} = 7.9, 2 CH), 7.11 (m, 6 CH), 7.21 (d, ³J_{HH} = 7.8, CH), 7.52 (t, ³J_{HH} = 7.8, 2 CH), 7.54 (d, ³J_{HH} = 6.9, CH) ppm; ¹³C NMR: 44.9 (d, ¹J_{CP} = 133.1, CH), 52.7 (d, ²J_{CP} = 7.2, CH), 53.4 (OMe) , 53.7 (OMe), 111.1 (2 CH), 118.2 (C), 120.0 (d, ³J_{CP} = 4.7, 2 CH_{ortho}), 120.1 (d, ³J_{CP} = 4.7, 2 CH_{ortho}), 125.5 (C), 124.1 (CH), 125.6 (CH_{para}), 125.7 (CH_{para}), 138.4 (CH), 129.8 (m, 4 CH_{meta}), 149.7 (m, 2 C_{ipso}), 166.6 (d, ²J_{CP} = 21.0, C=O), 158.8 (C=O), 167.7 (d, ³J_{CP} = 4.7, C=O), 181.3 (C=O) ppm; ³¹P NMR: 10.20 ppm; EI-MS: 523 (M⁺, 5), 430 (54), 376 (54), 285 (100), 147 (92), 92 (56), 77 (92).

Orange powder, mp 158-160°C; yield 0.86 g, 89%; IR (KBr): $\overline{V} = 1724$, 1608 cm⁻¹; ¹H NMR: 1.20 (*s*, CMe₃), 1.35 (*s*, CMe₃), 2.86 (d, ³J_{HP} = 10.9, OMe), 3.66 (d, ³J_{HP} = 10.5, OMe), 4.35 (dd, ³J_{HH} = 12.2, ²J_{HP} = 21.3, CH), 5.67 (dd, ³J_{HH} = 12.1, ³J_{HP} = 9.7, CH), 7.11 (d, ³J_{HH} = 7.3, CH), 7.20 (t, ³J_{HH} = 7.3, CH), 7.58 (t, ³J_{HH} = 7.4, CH), 7.54 (d, ³J_{HH} = 7.4, CH) ppm; ¹³C NMR: 27.6 (CMe₃), 27.4 (CMe₃), 44.6 (d, ¹J_{CP} = 132.8, CH), 52.1 (d, ²J_{PC} = 7.1, CH), 52.4 (d, ²J_{PC} = 7.0, OMe), 53.9 (d, ²J_{PC} = 7.1, OMe), 84.7 (CMe₃), 85.2 (CMe₃), 111.3 (2 CH), 116.9 (C), 123.6 (CH), 124.9 (C), 136.8 (CH), 162.1 (C=O), 167.3 (d, ²J_{CP} = 21.3, C=O), 171.2 (d, ³J_{CP} = 9.1, C=O), 182.3 (C=O) ppm; ³¹P NMR: 11.67 ppm; EI-MS: 483 (M⁺, 5), 452 (52), 374 (100), 337 (38), 146 (88), 109 (82), 73 (62), 57 (56), 31 (54). Yellow crystals, mp 136-138°C; yield 0.91 g, 88%; IR (KBr): \overline{V} = 1735, 1615 cm⁻¹; ¹H NMR: 1.18 (t, ³J_{HH}) = 6.7, Me), 1.21 (t, ${}^{3}J_{HH} = 6.7$, Me), 1.25 (s, CMe₃), 1.30 (s, CMe₃), 3.92 (m, OCH₂), 4.01 (m, OCH₂), 4.25 (dd, ${}^{3}J_{\text{HH}} = 12.0$, ${}^{2}J_{\text{HP}} = 21.0$, CH), 5.56 (dd, ${}^{3}J_{\text{HH}} = 11.9$, ${}^{3}J_{\text{HP}} = 9.5$, CH), 6.93 (d, ${}^{3}J_{\text{HH}} = 7.9$, CH), 7.11 (t, ${}^{3}J_{\rm HH}$ = 7.5, CH), 7.55 (t, ${}^{3}J_{\rm HH}$ = 7.7, CH), 7.59 (d, ${}^{3}J_{\rm HH}$ = 7.4, CH) ppm; ¹³C NMR: 16.2 (d, ${}^{3}J_{CP} = 6.2$, Me), 16.6 (d, ${}^{3}J_{CP} = 6.0$, Me), 27.2 (CMe₃), 27.9 (CMe₃), 46.2 (d, ${}^{1}J_{CP} = 130.8$, CH), 52.5 (d, ${}^{2}J_{CP} = 6.9$, CH), 63.9 (d, ${}^{2}J_{PC}$ = 7.3, OMe), 64.4 (d, ${}^{2}J_{PC}$ = 7.2, OMe), 83.2 (CMe₃), 84.3 (CMe₃), 110.5 (2 CH), 117.9 (C), 123.8 (CH), 124.5 (C), 138.3 (CH), 157.9 (C=O), 166.9 (d, ${}^{2}J_{CP} =$ 21.1, C=O), 169.0 (d, ${}^{3}J_{CP} = 14.0$, C=O), 182.1 (C=O) ppm; ³¹P NMR: 19.04 ppm; EI-MS: 511 (M⁺, 10), 418 (52), 365 (92), 278 (68), 233 (76), 146 (88), 93 (100), 73 (62), 57 (56).

References

[1] Kalaria, P. N.; Karad, S. C.; Raval, D. K. *Eur. J. Med. Chem.* **2018**, *158*, 917–936.

- [2] Desai, N.; Trivedi, A.; Pandit, U.; Dodiya, A.; Rao, V. K.; Desai, P. *Mini. Rev. Med. Chem.* **2016**, *16*, 1500–1526.
- [3] Fouad, M. M.; El-Bendary, E. R.; Suddek, G. M.; Shehata, I. A.; El-Kerdawy, M. M. *Bioorg. Chem.* **2018**, *81*, 587–598.
- [4] Martins, P.; Jesus, J.; Santos, S.; Raposo, L. R.; Roma-Rodrigues, C.; Baptista, P. V.; Fernandes, A. R. *Molecules* 2015, 20, 16852–16891
- [5] Siddiqui, N.; Andalip Bawa, S.; Ali, R.; Afzal, O.; Akhtar, M. J.; Azad, B.; Kumar, R. *J. Pharm. Bioallied. Sci.* **2011**, *3*, 194–212.
- [6] Sokolova, A. S.; Yarovaya, O. I.; Bormotov, N. I.; Shishkina, L. N.; Salakhutdinov, N. F. *Med. Chem. Comm.* **2018**, *9*, 1746–1753.
- [7] Goel, A.; Agarwal, N.; Singh, F. V.; Sharon, A.; Tiwari, P.; Dixit, M.; Pratap, R.; Srivastava, A. K.; Maulik, P. R.; Ram, V. J. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 1089–1092.
- [8] Amir, M.; Javed, S. A.; Kumar, H. *Indian. J. Pharm. Sci.* **2007**, *69*, 337–343.
- [9] Li, W.; Zhao, S. J.; Gao, F.; Lv, Z. S.; Tu, J. Y.; Xu, Z. *Chemistry Select* **2018**, *3*, 10250–10254.
- [10] Zhao, X.; Chaudhry, S. T.; Mei, J. 2017, 121, 133–171.
- [11] Khattab, T. A.; Rehan, M. A. . Egypt. J. Chem. 2018, 61, 989–1018.
- [12] Lamberth, C.; Dinges, J. Bioactive heterocyclic compound classes: agrochemicals. Wiley-VCH Verlag GmbH & Co, KGaA, **2012**.
- [13] Khalilzadeh, M. A.; Yavari, I.; Hossaini, Z.; Sadeghifar, H. *Monatsh. Chem.* **2009**, *140*, 467–471.

[14] Khaleghi, F.; Din, L. B.; Jantan, I.; Yaacob, W. A.; Khalilzadeh, M. A. *Tetrahedron Lett.* **2011**, *52*, 7182-7184.

[15] Tietze, L. F.; Bsasche, C.; Gericke, K. M. Domino reactions in organic synthesis. Wiley-VCH, Weinheim, **2006**.

[16] Weber L, Illgen M, Almstetter M. Synlett **1999**, *3*, 366–374

[17] Herrera, R. P.; Marqués-López, E. Multicomponent reactions: concepts and applications for design and synthesis. Wiley, Hoboken **2015**.

[18] Holmes, R. R. Acc Chem Res 2004, 37, 746

[19] Maryanoff, B. E.; Reitz, A. B. Chem Rev 2005, 89, 863

[20] Yavari, I.; Adib, M.; Hojabri, L. Tetrahedron **2001**, *57*, 7537.

[21] Corbridge, D. E. C. Phosphorus. An Outline of Its Chemistry, Biochemistry and Uses, 5th edn, Elsevier, Amsterdam, **1995**.

[22] Engle, R. Synthesis of Carbon-Phosphorus Bond, CRC Press, Boca Raton, FL, **1988**.

[23] Cadogan, J. I. G. Organophosphorus Reagents in Organic Synthesis, Academic Press, New York, **1977**.

[24] Arduago, A. J.; Stewart, C. A., *Chem Rev* **2001**, *94*, 1215.

[25] Pietrusiewiz, K. M.; Zabloka, M. Chem Rev 2005, 94, 1375.

[26] Bestmann, H. J.; Vostrowsky, O. *Top Curr Chem* **1983**, *109*, 85

[27] George, M.; Khetan, V. S. K.; Gupta, R. K. Adv *Heterocycl Chem* **2008**, *19*, 354

[28] Burgada, R.; Leroux, Y.; Zabloka, M.; Elkhoshnieh, Y. U. *Tetrahedron Lett* **2010**, *22*, 3533

[29] Hudson, H. R. The Chemistry of Organophosphorus Compounds, Volume 1. Primary, Secondary and Tertiary Phosphines, Polyphosphines and Heterocyclic Organophosphorus (III)Compounds, ed. F. R. Hantely, Wiley, New York, **1990**, 386.